Triglyceride-glucose index as a prognostic indicator in advanced gastric cancer: Insights and future research

Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment str...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 31; no. 17; p. 104794
Main Authors Zhao, Cheng-Fei, Liu, Xiao-Ling, Wu, Ning-Bi, Xu, Zhi-Feng
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 07.05.2025
Subjects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biomarkers, Tumor - blood
Blood Glucose - analysis
Humans
Immunotherapy - methods
Neoplasm Staging
Precision Medicine - methods
Prognosis
Progression-Free Survival
Stomach Neoplasms - blood
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach Neoplasms - therapy
Treatment Outcome
Triglycerides - blood
Triglyceride-glucose index
Insulin resistance
Advanced gastric cancer
Prognostic indicator
Immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Gastric cancer (GC), the fifth most common malignancy worldwide, poses a substantial challenge in clinical oncology, particularly in its advanced stages. Despite advancements in immunotherapy, patient prognosis remains poor, underscoring the need for reliable prognostic tools to refine treatment strategies. A study by Yao et al explores the role of the triglyceride-glucose (TyG) index as a prognostic marker for advanced GC patients receiving immunotherapy combined with chemotherapy. The results of the study demonstrate that the TyG index correlates with improved survival outcomes, including better progression-free survival and overall survival. This editorial critically evaluates the significance of these findings, discusses their implications for future research, and highlights innovative directions that could drive further breakthroughs in the application of the TyG index to cancer therapy. This editorial also highlights the potential of TyG in advancing precision oncology and advocates for global validation and mechanistic investigations to further solidify its clinical utility. Future research should focus on validating the TyG index across various malignancies, exploring its potential to influence immunotherapy through metabolic interventions, and developing multi-biomarker models that integrate TyG with immune and genomic profiles.
Bibliography:SourceType-Scholarly Journals-1
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
Author contributions: Zhao CF and Xu ZF designed this paper; Zhao CF and Liu XL wrote the paper; Zhao CF, Liu XL, Wu NB, and Xu ZF checked and proofread the paper, and searched related literature and information for this paper; all the authors have read and approved the final manuscript.
Supported by the Natural Science Foundation of Fujian Province, No. 2023J01160; Scientific Research Project of Putian University, No. 2022059; and Special Project for Outstanding Young Talents of Putian University, No. 2024072.
Corresponding author: Zhi-Feng Xu, Chief Physician, Department of Cardiothoracic Surgery, Affiliated Hospital of Putian University, No. 999 Dongzhen Road, Licheng District, Putian 351100, Fujian Province, China. zhifengxu1972@163.com
Co-first authors: Cheng-Fei Zhao and Xiao-Ling Liu.
ISSN:1007-9327
2219-2840
2219-2840
DOI:10.3748/wjg.v31.i17.104794